{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:26:20Z","timestamp":1760369180722},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T00:00:00Z","timestamp":1399248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172782"],"award-info":[{"award-number":["81172782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2016,4]]},"abstract":"Abstract<\/jats:title>Aim<\/jats:title>To evaluate the efficacy of tumor necrosis factor inhibitor infliximab in patients with rheumatoid arthritis (RA<\/jats:styled-content>) who were disease\u2010resistant to recombinant human interleukin\u20101 receptor antagonist (IL<\/jats:styled-content>\u20101Ra).<\/jats:p><\/jats:sec>Methods<\/jats:title>A total of 104 patients with active RA<\/jats:styled-content> despite methotrexate (MTX<\/jats:styled-content>) treatment were enrolled in the open trial. Among them, 27 IL<\/jats:styled-content>\u20101Ra nonresponders \u2018Switchers\u2019 and 51 biologic\u2010naive patients \u2018Naivers\u2019 received an infusion of 3\u00a0mg\/kg infliximab at weeks 0, 2, 6 and 14, combined with concurrent MTX<\/jats:styled-content> therapy, while the other 26 patients who had never received any biologics \u2018Controls\u2019 continued MTX<\/jats:styled-content> monotherapy. Clinical outcomes and safety were assessed at weeks 0, 2 and every 4\u00a0weeks thereafter for 18\u00a0weeks with the American College of Rheumatology (ACR<\/jats:styled-content>) core set criteria, the Disease Activity Score in 28 joints, and records of adverse events (AE<\/jats:styled-content>s) and abnormal laboratory findings.<\/jats:p><\/jats:sec>Results<\/jats:title>At week 18, an ACR<\/jats:styled-content>20 response was achieved in 56% of Switchers and 61% of Naivers, compared with 23% of Controls (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.0013 and 0.0126, respectively). Compared with Controls, both Switchers and Naivers achieved a significant improvement in tender\u2010joint count, swollen\u2010joint count, patient's assessment of pain, patient's and physician's global assessment of disease activity, erythrocyte sedimentation rate and C\u2010reactive protein. Switchers even achieved a greater benefit from health assessment questionnaire (HAQ<\/jats:styled-content>) scores than Naivers. Infliximab was well tolerated, with a similar incidence of AE<\/jats:styled-content>s across all study groups.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Switching from IL<\/jats:styled-content>\u20101Ra to infliximab is effective in improving disease activity and maintaining joint function.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12387","type":"journal-article","created":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T05:52:44Z","timestamp":1399269164000},"page":"370-376","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Good response to infliximab in rheumatoid arthritis following failure of interleukin\u20101 receptor antagonist"],"prefix":"10.1111","volume":"19","author":[{"given":"Jun","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Pediatrics Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China"},{"name":"Department of Rheumatology & Immunology Shanghai Changzheng Hospital Second Military Medical University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shanghai Guanghua Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Immunology Shanghai Changzheng Hospital Second Military Medical University Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong\u2010Yi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Shanghai Guanghua Hospital Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi\u2010Xiao","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,5]]},"reference":[{"issue":"65","key":"e_1_2_9_2_1","first-page":"22","article-title":"Tides of inflammation: impact of biologics","volume":"29","author":"St. Clair EW","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22331"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem072"},{"key":"e_1_2_9_8_1","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"33","author":"Gartlehner G","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_9_9_1","first-page":"C003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer B","year":"2002","journal-title":"Cochrane Database Systematic Rev"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/698523"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.01.005"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:39:16Z","timestamp":1696466356000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,5]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/1756-185X.12387"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12387","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,5]]},"assertion":[{"value":"2014-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}